Rivals’ disappointing data in asthma trial drag down shares of AnaptysBio

Rivals’ disappointing data in asthma trial drag down shares of AnaptysBio

Rivals’ disappointing results in asthma trial drag down shares of AnaptysBio

By ADAM FEUERSTEIN

KRISTOFFER TRIPPLAAR/SIPA VIA AP

A monoclonal antibody drug targeting a protein called IL-33 provided no additional benefit to asthma patients when added to Dupixent.

READ MORE